Atlas Trials

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT03399799 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03399799
Sponsor
Janssen Research & Development, LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Hematological Malignancies
Start date
2017-12-16
Primary completion
2022-07-07
Enrollment
279

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.